The new project will focus on detailed cell-based studies to further advance the validation of novel oncology target candidates successfully identified by Cenix in screens completed recently for AstraZeneca. Both the original screens and the new validation work are driven by the core Cenix expertise in combining high throughput RNAi-based gene silencing with high content phenotypic analyses, said Cenix.
Cenix will adapt and implement multi-parametric microscopy-based analyses of RNAi-induced loss-of-function phenotypes using the Cellenger image analysis platform from Munich-based Definiens, to generate detailed insights into the cellular functions and therapeutic development potential of tested genes.
Christophe Echeverri, CEO and chief scientific officer of Cenix, said: “We view the success of these first quite ambitious screens now completed for our colleagues at AstraZeneca as a clear testament to the strong scientific, technical and strategic synergies jointly achieved between our two teams. We welcome the chance to continue assisting AstraZeneca in the crucially important process of target validation to further advance their oncology pipeline.”